Fig. 4

Graphical representation of overall survival (OS) for a trials of NCCN-recommended (v1.2016) second-line (2L) plus monotherapy (including studies mixed with first-line [1L]), and b trials of NCCN-recommended (v1.2016) 1L monotherapy; the size of the bubble is proportional to the study size (all-patients-as-treated population), and the color of the bubble indicates the line of therapy. Yellow = 1L, green = 2L–3L+, pink = 2L, blue = 1L–3L+ (including studies with ≤ 15% 1L patients). Study 301 result is based on internal communication with trial sponsor (Eisai); not published results. OS from phase II 2015 study is based on a total of 86 patients, including 80% 1L and 20% 2L+ patients